Abstract
Background Asthma is one of the most common chronic conditions worldwide, with a substantial individual, societal and healthcare burden. Digital apps hold promise as a highly accessible, low-cost method of enhancing self-management in asthma, which is critical to effective asthma control.
Objective We conducted a fully remote trial to assess the efficacy of juli, a commercially available smartphone self-management platform for asthma.
Methods We conducted a pragmatic single-blind, randomized controlled trial of juli for asthma management. Our study included participants aged 18 and above with asthma and had an asthma control test (ACT) score of 19 or less (indicating poorly controlled asthma) at the beginning of the trial. Participants were randomized (1:1 ratio) to receive juli for eight weeks or a limited attention-placebo control version of the app. The primary endpoint was the difference in ACT scores after eight weeks. Secondary endpoints included eight-week remission (ACT score greater than 19), minimal clinically important difference (an improvement of three or more points on the ACT), worsening of asthma, and health-related quality of life. The primary analysis included participants using the app for eight weeks (per-protocol), a secondary analysis used modified intention-to-treat.
Results We randomized 411 participants between May 2021 and April 2023: 152 engaged with the app for eight weeks and were included in the per-protocol analysis, 262 completed the week two outcome assessment and were included in the modified intention-to-treat analysis.
In the per-protocol analysis, the intervention group had a higher mean ACT score (17.93, standard deviation = 4.72) than the control group (16.24, standard deviation = 5.78) by week eight (baseline adjusted β-coefficient 1.91, 95% confidence intervals = 0.31 to 3.51, p=0.020). Participants using juli had greater odds of achieving or exceeding the minimal clinically important difference at eight weeks (adjusted odds ratio = 2.38, 95% confidence intervals = 1.20 to 4.70, p=0.013). There were no between-group differences in the other secondary outcomes at eight weeks. The results from the modified intention-to-treat analysis were similar.
Conclusions Users of juli had improved asthma symptom control over eight weeks compared with users of a version of the app with limited functionality. These findings suggest that juli is an effective digital self-management platform that could augment existing care pathways for asthma.
Trial Registration The trial was pre-registered (ISRCTN87679686).
Competing Interest Statement
The current study was funded by juli Health. AK, BD, BH, JS and JFH are shareholders in juli Health. AK has received consultancy fees from juli Health and Wellcome Trust. BD, BH, JS and JFH are co-founders of juli Health. JFH has received consultancy fees from juli Health and Wellcome Trust. KE has no conflicts of interest. The funders played no part in the analysis of the data.
Clinical Trial
ISRCTN87679686
Clinical Protocols
https://discovery.ucl.ac.uk/id/eprint/10129351/
Funding Statement
AK is supported by the UK Research and Innovation (UKRI) Digital Youth Programme award [MRC project reference MR/W002450/1], which is part of the AHRC/ESRC/MRC Adolescence, Mental Health and the Developing Mind programme. JFH is supported by the UK Research and Innovation grant MR/V023373/1, the University College London Hospitals NIHR Biomedical Research Centre, and the NIHR North Thames Applied Research Collaboration.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University College London Ethics Committee gave full ethical approval (ID: 19413/001).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
